...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA >Long-term prospective study of osteoporotic patients treated with percutaneous vertebroplasty after fragility fractures.
【24h】

Long-term prospective study of osteoporotic patients treated with percutaneous vertebroplasty after fragility fractures.

机译：脆性骨折后经皮椎体成形术治疗骨质疏松患者的长期前瞻性研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

SUMMARY: This paper presents a prospective study on factors that could influence fracture risk after percutaneous vertebroplasty (PVP) in 115 osteoporotic patients. The mean follow-up was 39 months. The incidence of new fractures after PVP was 27.8%. Low body mass index (BMI), bone mineral density (BMD), and vitamin D are factors associated with increased risk of new fractures. INTRODUCTION: The purpose of this study was to evaluate factors that could increase the occurrence of new vertebral fractures (VFx) after PVP. METHODS: In our prospective study, we included patients of both sexes with osteoporosis (OP) and at least one painful VFx. We performed a baseline biochemical evaluation (including vitamin D plasma levels) and collected demographic, BMD, and clinical data. One hundred fifteen patients were treated with PVP and assigned to oral bisphosphonates plus Ca and vitamin D. The patients returned to control visits after 1, 3, and 6 months and every 6 months thereafter. X-rays film of the dorsolumbar spine was repeated every 12 months, or in case of pain that would suggest VFx occurrence. RESULTS: The mean follow-up was 39 +/- 16 months (range, 15-79). Thirty-two patients (27.8%) had new fragility VFx, all symptomatic. All the fractured patients agreed to undergo a new PVP. We compared the patients who had new VFx to those who had not, and we found significantly lower BMI, total hip, and femoral neck T-scores in the group with new VFx. Furthermore, baseline plasma levels of 25(OH) vitamin D (25(OH)D) were significantly lower in this group. Upon analyzing plasma levels of 25(OH)D 12 months after PVP, we found that a significant difference still persisted: 22 +/- 12 (group with new VFx) vs. 41 +/- 22 ng/ml (group with no VFx; p < 0.01). CONCLUSION: We found that in patients with OP treated with PVP, the incidence of new VFx was 27.8% after 39 months; low BMI, BMD, and vitamin D are factors associated with increased risk of new VFx in patients treated with PVP.
机译：摘要：本文对115名骨质疏松患者经皮椎体成形术（PVP）后可能影响骨折风险的因素进行了前瞻性研究。平均随访39个月。 PVP后新骨折的发生率为27.8％。低体重指数（BMI），骨矿物质密度（BMD）和维生素D是与新骨折风险增加相关的因素。简介：本研究的目的是评估可能增加PVP后新椎体骨折（VFx）发生率的因素。方法：在我们的前瞻性研究中，我们纳入了患有骨质疏松症（OP）和至少一种疼痛性VFx的男女患者。我们进行了基线生化评估（包括维生素D血浆水平），并收集了人口统计学，BMD和临床数据。 115名患者接受了PVP治疗，并分配了口服双膦酸盐加Ca和维生素D。这些患者在1、3、6个月后以及之后的每6个月恢复对照。每隔12个月或在出现表明VFx发生的疼痛的情况下，重复进行背脊柱X射线胶片。结果：平均随访时间为39 +/- 16个月（范围15-79）。 32例患者（27.8％）出现新的脆性VFx，均伴有症状。所有骨折的患者都同意接受新的PVP。我们将患有新VFx的患者与未患有新VFx的患者进行了比较，发现使用新VFx的患者的BMI，全髋关节和股骨颈T分值明显降低。此外，该组中血浆25（OH）维生素D（25（OH）D）的血浆水平显着降低。通过分析PVP后12个月的血浆25（OH）D水平，我们发现仍然存在显着差异：22 +/- 12（新VFx组）与41 +/- 22 ng / ml（无VFx组） ; p <0.01）。结论：我们发现在接受PVP治疗的OP患者中，新的VFx的发生率在39个月后为27.8％。低BMI，BMD和维生素D是与PVP治疗的患者中新VFx风险增加相关的因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号